FDA Accepts BLA for Datopotamab Deruxtecan in NSCLC, Grants Priority Review
FDA Approval of Tislelizumab: RATIONALE-305 Findings and Implications for Practice
Does Sickle Cell Trait Increase VTE Risk in Pregnant Women of African Ancestry?